Topiramate: Brands, Price & Uses in Bangladesh

Topiramate is an anticonvulsant (antiepileptic) medicine with the following evidence-based indications:

Established / FDA-approved uses

• Epilepsy - monotherapy: Initial monotherapy in patients 2 years of age and older with partial-onset or primary generalized tonic-clonic seizures.
• Epilepsy - adjunctive therapy: As add-on therapy in patients 2 years of age and older for partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome.
• Migraine prophylaxis: Prevention of migraine headache in adults and adolescents 12 years and older. Topiramate is not indicated for acute treatment of a migraine attack.

Off-label / combination use

• Topiramate is used off-label, in fixed-dose combination with phentermine, for chronic weight management in adults with obesity or overweight with weight-related comorbidities, as an adjunct to diet and exercise. This use requires combination therapy and specialist supervision; it is not indicated as monotherapy for weight loss.
• Other off-label uses reported in the literature (e.g., cluster headache prevention, essential tremor, certain mood/impulse-control disorders) are not FDA-approved and should only be considered under specialist guidance.

Epilepsy - Monotherapy (Adults and children ≥10 years)

Initiate at 25 mg once daily in the evening for one week, then titrate gradually (weekly or biweekly increments) to a target maintenance dose of 100 mg twice daily (200 mg/day), as tolerated. Some patients may require higher doses.

Epilepsy - Adjunctive Therapy (Adults)

Initiate at 25-50 mg/day, titrated weekly by 25-50 mg increments to a usual maintenance dose of 200-400 mg/day in two divided doses.

Epilepsy - Adjunctive Therapy (Children 2-16 years)

Weight-based initial dosing (approximately 1-3 mg/kg/day at bedtime), titrated gradually over several weeks to a target maintenance dose of approximately 5-9 mg/kg/day in two divided doses, guided by clinical response and tolerability.

Migraine Prophylaxis (Adults and adolescents ≥12 years)

Initiate at 25 mg nightly for one week, then increase by 25 mg/day at weekly intervals to a usual target dose of 100 mg/day in two divided doses. Slower titration may reduce cognitive and other adverse effects.

Renal Impairment

In patients with moderate to severe renal impairment (creatinine clearance ≤70 mL/min/1.73m²), a 50% reduction of the usual starting and maintenance dose is recommended, with slower titration. Supplemental doses may be needed after hemodialysis.

Hepatic Impairment

Use with caution in moderate to severe hepatic impairment, as clearance may be reduced.

Administration

May be taken with or without food. Tablets should be swallowed whole (avoid breaking, as they have a bitter taste); sprinkle capsules may be swallowed whole or opened and sprinkled onto a small amount of soft food and swallowed immediately without chewing. Maintain adequate hydration during treatment, particularly in hot weather or with physical activity, to reduce the risk of kidney stones. Topiramate should not be stopped abruptly; discontinuation should be gradual, under medical supervision, to minimize the risk of increased seizure frequency.

Common and important adverse effects of Topiramate include:

Common

• Paresthesia (tingling of the extremities)
• Fatigue, drowsiness, dizziness
• Cognitive and psychomotor slowing - difficulty with concentration, memory, and word-finding (a distinguishing feature of this medicine, sometimes referred to informally by patients as feeling "foggy," though this is not a clinical term)
• Decreased appetite and weight loss
• Nausea, taste alteration (especially with carbonated beverages)

Serious - require prompt medical attention

• Acute myopia with secondary angle-closure glaucoma: A rare but serious ocular syndrome, typically occurring within the first month of use, presenting as acute onset of blurred vision and/or eye pain. This is a medical emergency; Topiramate should be discontinued as rapidly as possible under a physician's guidance if this occurs, to prevent permanent vision loss.
• Metabolic acidosis: Topiramate can cause hyperchloremic, non-anion gap metabolic acidosis due to renal bicarbonate loss. This may be asymptomatic or present with hyperventilation, fatigue, or anorexia. Chronic untreated acidosis may contribute to nephrolithiasis (kidney stones), reduced bone density (osteoporosis/osteomalacia), and, in children, may affect growth. Periodic monitoring of serum bicarbonate is recommended.
• Suicidal thoughts or behavior: As with other antiepileptic drugs as a class, Topiramate is associated with a small increased risk of suicidal ideation or behavior. Patients and caregivers should be alert to mood changes, unusual behavior, or emergence of suicidal thoughts, and report these immediately.
• Oligohidrosis and hyperthermia: Decreased sweating leading to elevated body temperature, which can be serious, especially in children exposed to high ambient temperatures or during vigorous exercise. Adequate hydration and avoidance of excessive heat exposure are advised.
• Kidney stones: Increased risk of nephrolithiasis; adequate fluid intake is recommended to reduce risk.
• Mood changes, depression, and irritability.